Cargando…

Detection and Characterization of Estrogen Receptor α Expression of Circulating Tumor Cells as a Prognostic Marker

SIMPLE SUMMARY: CTCs are considered the seeds of metastases and their presence in the blood is related to survival in breast cancer. Estrogen receptor (ER) is considered a direct target of hormonal therapy. Evaluating the expression of ER in CTCs to characterize the tumor and assess therapy efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ningsi, Retno, Elazezy, Maha, Stegat, Luisa, Laakmann, Elena, Peine, Sven, Riethdorf, Sabine, Müller, Volkmar, Pantel, Klaus, Joosse, Simon A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179654/ https://www.ncbi.nlm.nih.gov/pubmed/35681601 http://dx.doi.org/10.3390/cancers14112621

Ejemplares similares

BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
por: Elazezy, Maha, et al.
Publicado: (2021)

Emerging Insights into Keratin 16 Expression during Metastatic Progression of Breast Cancer
por: Elazezy, Maha, et al.
Publicado: (2021)

Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management
por: Elazezy, Maha, et al.
Publicado: (2018)

Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients
por: Babayan, Anna, et al.
Publicado: (2013)

Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch(®) System and the AdnaTest(®)
por: Gorges, Tobias M., et al.
Publicado: (2016)

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study
por: Müller, Volkmar, et al.
Publicado: (2012)

Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases
por: Mohme, Malte, et al.
Publicado: (2017)

Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)
por: Bergmann, Sonja, et al.
Publicado: (2020)

Circulating tumor cells and extracellular vesicles as liquid biopsy markers in neuro-oncology: prospects and limitations
por: Westphal,, Manfred, et al.
Publicado: (2022)

Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease
por: Hanssen, Annkathrin, et al.
Publicado: (2018)

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2016)

Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients
por: Koch, Claudia, et al.
Publicado: (2020)

Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives
por: Müller, Volkmar, et al.
Publicado: (2004)

Clonality of circulating tumor cells in breast cancer brain metastasis patients
por: Riebensahm, Carlotta, et al.
Publicado: (2019)

Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer
por: Gorges, Tobias M., et al.
Publicado: (2016)

EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients
por: Scharpenseel, Heather, et al.
Publicado: (2019)

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Müller, Volkmar, et al.
Publicado: (2011)

Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer
por: Roth, Carina, et al.
Publicado: (2010)

Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients
por: Riethdorf, Sabine, et al.
Publicado: (2009)

Biology, detection, and clinical implications of circulating tumor cells
por: Joosse, Simon A, et al.
Publicado: (2015)

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2017)

Recent translational research: circulating tumor cells in breast cancer patients
por: Müller, Volkmar, et al.
Publicado: (2006)

Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma
por: Fründt, Thorben, et al.
Publicado: (2022)

Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients
por: Kuske, Andra, et al.
Publicado: (2016)

Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer
por: Hille, Claudia, et al.
Publicado: (2019)

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients
por: Meng, Xiaodan, et al.
Publicado: (2015)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence
por: Knipper, Sophie, et al.
Publicado: (2021)

A Versatile Microarray Platform for Capturing Rare Cells
por: Brinkmann, Falko, et al.
Publicado: (2015)

Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression
por: Roth, Carina, et al.
Publicado: (2011)

Circulating microRNAs: promising breast cancer biomarkers - authors' response
por: Roth, Carina, et al.
Publicado: (2011)

Chronic UVB-irradiation actuates perpetuated dermal matrix remodeling in female mice: Protective role of estrogen
por: Röck, Katharina, et al.
Publicado: (2016)

Prognostic value of preoperative circulating tumor cells counts in patients with UICC stage I-IV colorectal cancer
por: Abdalla, Thaer S. A., et al.
Publicado: (2021)

The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy
por: Rink, Michael, et al.
Publicado: (2020)

Quantitative High-Resolution Genomic Analysis of Single Cancer Cells
por: Hannemann, Juliane, et al.
Publicado: (2011)

Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases
por: Joosse, S A, et al.
Publicado: (2014)

Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection
por: von Felden, Johann, et al.
Publicado: (2017)

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2018)

Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer
por: Meng, Xiaodan, et al.
Publicado: (2016)

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lcae9po4cpfq072g4b729dhb2f